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Ribavirin for Chronic
Hepatitis E in
Liver-Transplant
Setting: A Safe and
Highly Effective
Therapy
To the Editor:
Hepatitis E virus (HEV) chronic
infection has been increasingly recog-
nized among immunocompromised
patients. HEV infection is a cause of
graft hepatitis in liver-transplant (LT)
recipients and may result in chronic
infection, progressive fibrosis, and end-
stage liver disease in this population,
which seems to have a higher risk when
compared with non-LT patients.1
The authors report 5 cases of
HEV chronically infected LT recipi-
ents, successfully treated with rib-
avirin. These represent 3.5% of the 141
LT recipients with persistent unex-
plained elevated liver enzymes, tested
by HEV-RNA PCR after other possi-
ble causes were excluded. Prevalence of
HEV infection, in the setting of trans-
plantation, is not well known. How-
ever, it seems low in western transplant
cohorts. Behrendt et al2 recently sug-
gested that testing only patients with
elevated liver enzymes is a reasonable
approach, as we do in our center.
In 4 patients, familial amyloidotic
polyneuropathy was the initial liver
disease, and the fifth patient had Wil-
son’s disease. As expected, considering
these diagnoses, our patients were
younger than in other series, with a
mean age of 32 years at the time of
transplant (range, 27 to 35 y). The time
between the transplant and the evidence
of HEV infection had a wide range
(4mo to 11 y). No patients had an acute
rejection episode after undergoing
transplantation. Only 1 patient had an
acute self-limited symptomatic episode
of hepatitis, followed by persistent
raised transaminases levels. In the
remaining 4 patients, acute hepatitis was
asymptomatic, no abnormalities were
detected during physical examination
and HEV infection was diagnosed after
the detection of persistent abnormal
liver enzymes levels. All patients had
persistently normal platelet count and
hemoglobin level, and only 1 had mild
impaired renal function. Two patients
were infected by genotype 3 and in the
other 3 cases, HEV was not genotyped.
At the time of the infection diagnosis, 4
patients were medicated with tacroli-
mus. The use of tacrolimus (rather than
cyclosporine A) and a low platelet count
are the main independent predictive
factors for chronic infection.1 Reduc-
tions in immunosuppressive therapy
seem to result in viral clearance in only
one third of these patients. Recent data
suggests that various immunosup-
pressive regimens can differentially
affect HEV replication: in vitro steroids
have no significant effect on HEV rep-
lication, calcineurin inhibitors promoted
replication of HEV and mycophenolic
acid inhibits HEV replication.3 Appli-
cation of this knowledge into clinical
practice needs confirmation by large
comparative trials, before these data can
influence the choice of immunosup-
pressive regimens. In our patients we
reduced the overall level of immuno-
suppression. All of our patients were
also treated with ribavirin at a dose of
800 to 1200mg daily during 6 months.
After 3 months of therapy, all patients
had undetectable viremia. All of them
completed the treatment, and no
adverse effects were reported. At the end
of therapy, all patients had undetectable
HEV-RNA. Six months after finishing
antiviral therapy, all achieved sustained
virological response (SVR) and had
normal levels of liver enzymes. In our
case series, ribavirin monotherapy
showed to be safe and highly effective.
We had no adverse effects, namely
anemia. Therefore, we maintained the
same dose of ribavirin, which may jus-
tify our excellent results. Thus, some
studies reported the appearance of clin-
ical resistance with lower doses. With 6
months of therapy, SVR was achieved
in all of our patients. Shorter courses
can be related with recurrence cases. In
the recent series by Kamar et al,4 all
patients who failed to clear HEV during
the initial course of ribavirin therapy
showed a SVR when retreated for a
longer period. All of our patients have
>18 months of follow-up, with no signs
of recurrence. In a real world setting,
ribavirin for 6 months in weight-based
dose showed excellent results, however
this needs to be confirmed in large,
randomized, controlled trials.
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Élia Mateus, MDw
Ana Morbey, MDw
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Portal Hypertension
Related to
Schistosomiasis
Treated With a
Transjugular
Intrahepatic
Portosystemic Shunt
To the Editor:
Hepatosplenic schistosomiasis rep-
resents the most common form of
chronic intestinal schistosomiasis. Liver
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periportal fibrosis, leading to portal
hypertension, is the major cause of dis-
ease morbidity and mortality, due to
massive bleeding of esophageal or gastric
varices.1
Hereby, we present the case of a
30-year-old Ethiopian man who was
referred to our Unit for hematemesis.
Emergency endoscopy showed evidence
of active bleeding from varices of the
lower third of the esophagus. Endoscopic
rubber band ligation was performed. On
physical examination, splenomegaly
extending 4 cm below the costal margin
and moderate ascites without neuro-
logical disorders were found. Laboratory
tests showed leukopenia (white blood
cells: 2410/mm3), anemia (hemoglobin:
8.3 g/dL) with a hematocrit of 25%, and
thrombocytopenia (platelet: 47.000/
mm3). The liver function panel revealed
the following data: total bilirubin 1.7
mg/dL, alanine aminotransferase 93U/L
(upper normal limit <41U/L), aspar-
tate aminotransferase 85U/L (upper
normal limit <40U/L), international
normalized ratio 1.4, and albumin
3.4 g/dL (Child Pugh score B7). Hepatitis
A, B, and C, Cytomegalovirus, Epstein-
Barr virus, and human immunodeficiency
virus serology tests were negative. Trans-
ferrin saturation and serum ceruloplasmin
were within the normal values. Anti-
nuclear antibody, antismooth-muscle
antibody, antimitochondrial antibody,
and liver/kidney microsomal antibody
were also negative. Abdomen ultrasound
and computed tomography revealed fea-
tures of severe portal hypertension, such
as splenoportal axis ectasia, splenomegaly
(maximal diameter of 20cm), splenorenal
shunt, and moderate ascites. The hepatic
venous pressure gradient was 24mm Hg.
Despite esophageal band ligation, a pro-
gressive anemia due to intestinal blood
loss was observed and early transjugular
intrahepatic portosystemic shunt (TIPS)
was performed. TIPS insertion resulted in
a decrease in hepatic venous pressure
gradient to 9mm Hg and a reduction of
varices with a progressive increase in
hemoglobin levels. After TIPS placement,
no episodes of hepatic encephalopathy
(HE) occurred. Repeated stool examina-
tions demonstrated Schistosoma mansoni
eggs; schistosoma antibodies were
detected by serological test. A percuta-
neous ultrasound-guided liver biopsy,
performed at the time of TIPS placement,
did not show any sign of cirrhosis. Focal
matrix degradation characterized by
fragmentation and dispersion of collagen
fibers, hyperplasia of elastic tissue,
destruction of portal-vein radicles, sinus-
oidal dilatation and disarray of smooth
muscle fibers, the presence of bile pig-
ments, and hemosiderin were observed. S.
mansoni eggs were not detected in the liver
biopsy. The patient was diagnosed with
intestinal and hepatic schistosomiasis and
he was treated with praziquantel 40mg/
kg. The patient’s clinical conditions
improved progressively and he was dis-
charged after 10 days.
Worldwide, mansonic schistoso-
miasis is the second most prevalent
parasitosis after malaria, with 240
million estimated infected individuals,
90% of them residing in Africa. Mor-
tality is mainly caused by upper diges-
tive-tract hemorrhage, resulting from
portal hypertension.2
The management of acute upper
gastrointestinal bleeding in schistoso-
miasis is similar to that of cirrhosis.
Nevertheless, pharmacological treatment
with b-blockers is controversial due to
pulmonary hypertension. Although sys-
temic vasoconstrictors can be helpful,
band ligation or sclerotherapy of
esophageal varices is considered as the
optimal therapeutic strategy.3 Although
endoscopic rubber band ligation was
performed promptly for our patient, the
procedure was not conclusive because of
rebleeding. For patients with uncon-
trolled bleeding after medical and/or an
endoscopic approach, surgical proce-
dures are indicated,4 despite the risk of
encephalopathy after surgery. HE occurs
in nearly 40% of the patients undergoing
proximal splenorenal shunt surgery, a
percentage much greater than that of
patients undergoing distal splenorenal
shunt (14.8%) or splenectomy with
devascularization (0%).4,5 Therefore,
esophagogastric devascularization with
splenectomy should be considered as the
most effective procedure.3,6,7 Moreover,
considering the fact that the hepatic
function is not impaired in schistoso-
miasis-related disease,7 the surgical
treatment of portal hypertension in
patients with chronic schistosomiasis has
distinct features compared with cirrhotic
patients. Accordingly, Ezzat et al8
reported a significantly lower risk of HE
after selective surgical shunt in patients
with schistosomal hepatic fibrosis com-
pared with those with cirrhosis (4.4% vs.
23.5%, P<0.05). In our patient, we
preferred TIPS insertion, which, unlike
most surgical procedures, is far less
invasive and preserves the spleen and its
immunological function.9 Furthermore,
studies reporting outcomes of surgery
in schistosomiasis differ in surgical
methods and they do not describe sys-
tematically indirect adverse events of
splenectomy, such as infections.10,11 In
our case, TIPS was a conclusive proce-
dure, resulting in the reduction of portal
pressure and the interruption of upper
gastrointestinal bleeding. Recently, a
paper reporting similar results has been
published.10
In conclusion, we believe that
schistosomiasis has to be included in the
differential diagnosis of portal hyper-
tension, as its prevalence in Europe
might increase due to migration from
endemic regions. Although existing
guidelines on TIPS indication do not
consider this procedure as a therapeutic
option for schistosomiasis-related por-
tal hypertension,12 in our opinion, TIPS
should be taken into account as it rep-
resents an effective and less invasive
approach compared with surgery.
Therefore, for the better management
of schistosomiasis portal hypertension,
prospective studies are needed.
Stefania Grieco, MD*
Lucia Fontanelli Sulekova, MD*
Silvia Nardelli, MDw
Oliviero Riggio, PhDw
Mario Venditti, MDz
Gloria Taliani, PhD*
Departments of *Clinical Medicine
Infectious and Tropical Diseases Clinic
Policlinico Umberto I
wClinical Medicine, Centre for the Diagnosis
and Treatment of Portal Hypertension
zPublic Health and Infectious Diseases
“Sapienza” University of Rome
Rome, Italy
REFERENCES
1. Olveda DU, Olveda RM, McManus
DP, et al. The chronic enteropathogenic
disease schistosomiasis. Int J Infect Dis.
2014;28:193–203.
2. World Health Organization. Schistosomia-
sis: Progress Report 2001-2011, Strategic
Plan 2012-2020. Geneva: WHO; 2013.
3. Strauss E, Valla D. Non-cirrhotic portal
hypertension—concept, diagnosis and
clinical management. Clin Research Hep-
atol Gastroenterol. 2014;38:564–569.
4. Andersson KL, Chung RT. Hepatic
schistosomiasis. Curr Treat Options
Gastroenterol. 2007;10:504–512.
5. Raia S, da Silva LC, Gayotto LC, et al.
Portal hypertension in schistosomiasis:
a longterm follow-up of a randomized
trial comparing three types of surgery.
Hepatology. 1994;20:398–403.
6. Khanna R, Sarin SK. Non-cirrhotic
portal hypertension—diagnosis and man-
agement. J Hepatol. 2014;60:421–441.
7. Ferraz AA, Bacelar TS, Silveira MJ,
et al. Surgical treatment of schistosomal
portal hypertension. Int Surg. 2001;86:
1–8.
Copyright r 2016 Wolters Kluwer Health, Inc. All rights reserved.
J Clin Gastroenterol  Volume 50, Number 7, August 2016 Letters to the Editor
Copyright r 2016 Wolters Kluwer Health, Inc. All rights reserved. www.jcge.com | 609
8. Ezzat FA, Abu-Elmagd KM, Sultan
AA, et al. Schistosomal versus non-
schistosomal variceal bleeders. Do they
respond differently to selective shunt
(DSRS)? Ann Surg. 1989;209:
489–5009.
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Ocular Toxoplasmosis
Reactivation in
a Patient With
Inflammatory Bowel
Disease Under
Treatment With
Azathioprine
To the Editor:
Thiopurines are used widely in the
treatment of inflammatory bowel dis-
ease (IBD); however, they are asso-
ciated with opportunistic infections.1 It
is important to maintain a surveillance
of symptoms suggestive of infections in
these patients.
We expose the case of a 33-year-
old woman originally from Nigeria
who presented with a 24-hour history
of visual loss in the left eye and peri-
ocular pain. She was diagnosed of
ulcerative colitis, and treated with
mesalazine and azathioprine 100mg/24
hours for 12 months because of
corticodependency.
Her visual acuity was reduced to
counting fingers in the left eye. Oph-
thalmoscopy examination showed a
focus of chorioretinitis on the edge of
an old chorioretinal scar with retinal
detachment and the presence of retinal
vasculitis with venous and arterial
involvement. Blood test and cranial
computed tomography were normal.
Serological tests for HIV, Treponema
pallidum, Epstein-Barr, and cytomega-
lovirus were negative and the tox-
oplasma serology showed negative
IgM and positive IgG antibodies.
Clinical and ophthalmoscopic findings
were highly suggestive of ocular tox-
oplasmosis reactivation in an immu-
nocompromised patient, and she
was treated with sulfadiazine, pyr-
imethamin, folic acid, and prednisone
for 2 months. The response was sat-
isfactory with retinal reapplication
over 2 weeks and complete recovery of
visual acuity after 3 months.
Ocular toxoplasmosis is the most
common cause of retinochoroiditis
worldwide, usually presenting as photo-
phobia, blurred vision, and even blind-
ness. In immunosuppressed patients,
greater extension and severity have been
described, even with mortality due to
intracranial lesions. It is caused by the
protozoal parasite Toxoplasma gondii,
and in the United States, 22.5% of the
population 12 years or older has been
estimated to be infected. Cats are the
principal hosts and humans and other
vertebrate animals are the intermediate
hosts. It is fundamentally transmitted
through the oral and the transplacental
routes.
The diagnosis is based on clinical
and ophthalmoscopic findings. Serol-
ogy can support it, confirming expo-
sure to the parasite, but the diagnosis
of ocular toxoplasmosis cannot be
made on the basis of serological tests
because IgG titers are usually low, and
IgM can be negative because isolated
ocular reactivation is usually insuffi-
cient to produce a systemic immune
response,2 as shown in our case.
The treatment of toxoplasma
chorioretinitis in immunocompetent
patients is controversial because the
lesions usually resolve spontaneously.
Treatment is indicated in immunosup-
pressed patients and in the presence of
severe vitritis or lesions localized in the
macula or the optic nerve in immuno-
competent patients. Sulfadiazine-pyr-
imethamine, prednisone, and folic acid
(for the prevention of leukopoenia and
thrombocytopenia due to pyrimeth-
amine) is the standard treatment.1
Ocular toxoplasmosis reactivation
has been reported in immunocompro-
mised patients with ankylosing spon-
dylitis3 or after cardiac transplant,4 but
no cases have been reported in IBD
patients or relating to the use of thio-
purines. In our opinion, ocular tox-
oplasmosis should be considered in the
differential diagnosis of IBD patients
treated with thiopurines presenting
with ocular symptoms, especially if
they come from countries with high
endemia. The diagnosis should be
established as early as possible to avoid
fatal complications or severe sequelae.
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Mycosis Fungoides–
like Eruption
and Infliximab
To the Editor:
The increased use of TNF-a
inhibitors has led to focus on their
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